Detalhe da pesquisa
1.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med;
389(4): 335-347, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37272512
2.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Blood;
141(3): 219-230, 2023 01 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36095849
3.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med;
385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34192431
4.
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
BMC Cancer;
24(1): 541, 2024 Apr 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38684948
5.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica;
108(8): 2192-2204, 2023 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36546453
6.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet;
398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34175021
7.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol;
22(6): 801-812, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34087126
8.
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Blood;
134(5): 421-431, 2019 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31113777
9.
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.
Eur J Haematol;
107(4): 428-435, 2021 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34137077
10.
CNV Radar: an improved method for somatic copy number alteration characterization in oncology.
BMC Bioinformatics;
21(1): 98, 2020 Mar 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32143562
11.
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Haematologica;
105(2): 468-477, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31221782
12.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med;
375(8): 754-66, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27557302
13.
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Haematologica;
103(12): 2088-2096, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30237262
14.
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Haematologica;
103(12): 2079-2087, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30237264
15.
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
Clin Chem Lab Med;
54(6): 1095-104, 2016 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27028734
16.
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
Br J Haematol;
186(3): e35-e39, 2019 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30931524
17.
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Expert Opin Biol Ther;
24(5): 339-350, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38738379
18.
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
Clin Lymphoma Myeloma Leuk;
24(4): 224-231.e2, 2024 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38212206
19.
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
J Clin Oncol;
41(6): 1275-1284, 2023 02 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36269898
20.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin;
39(1): 81-89, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36271807